• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

Sanofi’s Retreat from the Diabetes Market

Biotech Letter

Investors on the lookout for a large-cap biotech investment have several options, with Sanofi SA (SNY) being one of the most captivating companies to consider.

The French multinational pharma giant has a diverse drug portfolio which has been attracting attention recently thanks to its focus on the lucrative market of diabetes treatments.

Unfortunately, the diabetes project hasn’t been working as well as Sanofi had hoped this year. Earlier in 2019, the FDA rejected the company’s new diabetes candidate Zynquista. Despite this setback, the company announced more promising Phase 3 results from another diabetes treatment, Toujeo, which is aimed at children and adolescents with Type 1 diabetes.

Regardless of the roadblocks encountered by Sanofi in its bid to dominate this lucrative market, the company has been insistent in this endeavor -- a determination that’s actually understandable given that the diabetes market covers over 425 million people worldwide.

So far, Sanofi has managed to be one of the leaders in this sector, with insulin injection pen Lantus working as a stable revenue driver for the biopharma for years now.

To offer a clearer perspective on the promising diabetes sector, Lantus raked in $3.95 billion in sales for 2018 alone -- impressive growth that has been attracting competitors left and right.

In fact, this Sanofi diabetes moneymaker has been experiencing steep competition with sales slipping by over $1.17 billion largely due to the emergence of cheaper and stronger rivals in the market.

Nonetheless, Sanofi wants to maintain its stronghold so new deals are expected to crop up soon in an effort to shore up its declining Lantus revenue.

Among the drugs in its portfolio, Toujeo has actually been doing quite well, raking in $930 million in sales in 2018. While this doesn’t really cover the $1.17 billion slip from Lantus sales over the same period, the figure is close enough to bring hope to investors and keep competitors at bay.

Sanofi’s strongest competitor, particularly in the diabetes market, is Novo Nordisk (NVO). The latter’s diabetes drug, Tresiba, has actually accounted for 84.2% of its overall sales.

While this is daunting for Sanofi, the sales performance of Tresiba can also highlight a key differentiator between the two. That is, Sanofi offers a more diversified portfolio especially in terms of revenue sources. Meanwhile, Novo Nordisk is focused on the diabetes market alone.

Although both Toujeo and Lantus have been remarkable in sales thus far, Sanofi has a number of other top-performing drugs in its portfolio. After all, Sanofi isn’t just about diabetes treatments.

In terms of growth, eczema treatment Dupixent has shown a remarkable 142% jump in sales over the past year. Its revenues rose to $628 million for the third quarter in 2019. In comparison, the overall sales for Sanofi’s diabetes treatments declined by 18% since the third quarter of 2018. 

While it’s easy to get distracted by the allure of the lucrative diabetes market, these treatments actually comprise a small portion of the French biopharma’s drug portfolio.

To date, Sanofi has 85 up-and-coming drugs, with 51 of these already sent to early clinical tests and the remaining 34 either in Phase 3 trials or sent for approvals.

To provide a more direct comparison, reports show that only two drugs in the pipeline are aimed towards the diabetes market. The rest of Sanofi’s portfolio has 28 oncology candidates and 18 immuno-inflammation drug prospects.

Overall, Sanofi has a stable, well-rounded portfolio to offer its investors. However, stiff competition can prove to be a huge obstacle, especially in the high-growth diabetes space. Its revenue growth in this sector isn’t also as remarkable as its competitors.

This doesn’t take away from Sanofi’s other products though. What it means is that it would be a better call to buy Sanofi stock once prices fall at a cheaper valuation.

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/12/sanofi-e1575976087552.png 232 500 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-10 06:00:132019-12-10 06:09:51Sanofi’s Retreat from the Diabetes Market
Mad Hedge Fund Trader

December 9, 2019 - MDT Alert (TEVA)

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to the six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-09 12:08:222019-12-09 12:08:22December 9, 2019 - MDT Alert (TEVA)
Mad Hedge Fund Trader

December 9, 2019 - MDT Pro Tips A.M.

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-09 09:20:472019-12-09 09:20:47December 9, 2019 - MDT Pro Tips A.M.
Mad Hedge Fund Trader

December 9, 2019

Diary, Newsletter, Summary

Global Market Comments
December 9, 2019
Fiat Lux
 

Featured Trade:

(MARKET OUTLOOK FOR THE WEEK AHEAD, or THE MELT-UP CONTINUES),
(SPY), (TLT), (VIX), (FXI)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-09 07:04:492019-12-09 07:37:42December 9, 2019
Mad Hedge Fund Trader

December 9, 2019

Tech Letter

Mad Hedge Technology Letter
December 9, 2019
Fiat Lux

Featured Trade:

(THE BEYOND MEAT BOMB),
(BYND), (TSN), (KRL), (K), (CAG)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-09 07:04:072019-12-09 06:48:13December 9, 2019
Mad Hedge Fund Trader

The Beyond Meat Bomb

Tech Letter

Food tech stock Beyond Meat, Inc. (BYND) went from euphoric to absolute dud when shares surged above $240 at the end of July only to crash.

In general, tech stocks have had a successful year, but the second half of the year has been inordinately unkind to growth stocks and Beyond Meat bore the full brunt of the change in market sentiment.

Let me remind you that I am not saying this is a bad company or a bad stock like Uber (UBER) or Lyft (LYFT).

Hardly so.

Investors can take away many positives from their overarching story and even more so as the stock has come down from the heavens settling in the mid-70’s range.

First, plant-based food is not going away anytime soon and is intertwined with the Millennial ethos of living healthier and protecting the planet.

Nonprofit organization The Good Foods Institute has forecasted that the plant-based food market is valued at more than $4.5 billion in the U.S. and grew 11% year over year.

Plant-based meat rose 10% last year, a substantial decrease of 25% year over year, but industry experts believe there is a significant pipeline of international revenue just waiting there for the taking.

More than one-third have tried at least one plant-based meat product, a low figure, but of those that have tasted, 57% make a repeat purchase.

Internationally, sales are expected to go from a $12.1 billion market in 2019 to a $27.9 billion market by 2025. In 2018, plant-based meat sales comprised 1% of all dollar sales in total retail meat in the U.S. and that number is only going to rise.

Let’s compare it with another successful plant-based product that has matured into a winner – milk.

This market has developed into a $1.86 billion market and plant-based milk is further ahead than the plant-based dairy and meat market.

Fortunately, these juxtaposed markets represent substantially overlap and positive demographic correlation of plant-based milk and meat consumers could mean that plant-based meat companies could achieve a similar rise like the plant-based milk companies experienced.

Domestically, plant-based milk now has a 13% share of the overall retail milk market, exploding by 61% from the years 2012 to 2017 and a further 6% rise in 2018.

If plant-based meat enters into the same trajectory as their cousins’ plant-based milk, grabbing 10% of market share from the overall retail meat market is feasible.

The special sauce that initially propelled the share price to the Himalayan highs of July was the insane growth rate which last quarter came in at 211.5% year-over-year.

The company is also surprisingly profitable eking out a $4.10 million performance last quarter on almost $92 million of quarterly revenue.

But I would like to bring investors back to reality and remind them that the company only does $92 million of revenue per quarter and the one before that a touch above $67 million.

This company is still in its infancy and just because it bursts with life in its formative stages does not mean investors can extrapolate that for years ahead.

What are the headwinds and how far off are they?

The most unstable variable rearing its ugly head is intense competition imminently barreling towards Beyond Meat.

An outsized dosage of competition would take an axe to profit margins with minimal chance of a quick reversal even if Beyond Meat manages to offer an outperforming product.

Beyond Meat is the disruptor and reaped a dividend from the first-mover advantage and the subsequent network effects.

But that doesn’t mean larger companies can’t copy them and that is exactly what is happening as we speak.

The competition is rapidly intensifying, specifically from big box protein processors and packaged food players who plan to undercut Beyond Meat price points using excess capacity and a lower gross margin rate profile.

The companies coming for Beyond’s bacon are Tyson Foods Inc. (TSN), Kellogg Co. (K), Hormel Foods Corp. (HRL), and Conagra Brands Inc. (CAG).

These big players will dump volume onto the plant-based food market and Kroger Co. just announced it would introduce 58 plant-based items under its private label Simple Truth in 2020.

Beyond Meat’s strategic position could suffer if consumers prove less brand loyalty and more price-conscious, then Beyond Meat’s first-mover advantage could dissipate and dynamics could revert closer to commodity industry profit margins.

Investors are laser-like focused if Beyond Meat can maintain gross margins over 35% by layering strategic partnerships with businesses that have a widespread addressable audience base.

If Beyond Meat fails in this respect, the competition will gradually destroy its competitive advantage and tank its share price.

The quality of the product has a large role to play in this too.

Another possible headwind is that Impossible Foods’ Impossible Burger is favored by many taste experts in taste tests diminishing Beyond’s product to the second tier.

But If the company can mimic the taste of a high-quality burger and replicate at least 80% of that experience, the products are likely to stick leading to more investment to capture that last 20% of the taste experience.

It is yet to be determined if Beyond Meat can muscle itself through the gauntlet of rigmaroles, and technically, its overhyped beginnings have given way to a more modest share price as of late.

If the stock enters into the $50 price range, it would be an advantageous price point to scale into this leader of food tech, but I would monitor it closely because the narrative could change on a dime and the story could sour if their strategy begins to fail.

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-09 07:02:482020-05-11 13:00:44The Beyond Meat Bomb
Mad Hedge Fund Trader

The Market Outlook for the Week Ahead, or the Melt-Up Continues

Diary, Newsletter

I can tell you that the way to NOT start writing a newsletter is to first swing a 20-pound sledgehammer for three hours. That's what I did this morning helping the Boy Scouts mount 700 trees on rebar stands as part of the annual Christmas tree fundraiser.

Nor is it advisable to start writing a newsletter by hauling 50-pound trees on to car rooftops and tying them down.

However, I am a man of my commitments, so here I am with the aid of a long hot bath and some Epsom salts.

With that said, I have only one number to announce: 55.61%. That is the profit that followers of the Mad Hedge Fund Trader have earned so far in 2019, and I know many of you are up a lot more than that.

All it took for me to achieve a new all-time high was to turn aggressive at the bottom of last week’s 900 selloff in the Dow Average.

With super liquidity flooding the financial system and ultra-low interest rates fanning the flames, I didn’t believe my Mad Hedge Market Timing Index would not fall below 60, where it held.

I also thought that, with so many buyers clamoring to get into the market, no pullbacks would go beyond 3%, which also turned out to be true.

This prompted me to increase my “RISK ON” positions from 20% to 50%, the timing of which turned out to be perfect. That enabled me to coin a breathtaking +4.81% in performance last week, quite a big bite for this normally sedentary time of the year.

A sledgehammer of a different sort was taking to the shorts last week as a robust November Nonfarm Payroll Report sent share flying, up 266,000, a ten-month high. The Headline Unemployment rate dropped to 3.5%.

It was not entirely a rosy report, with 50% of the gains by those 55 and overtaking second jobs at paltry minimum $8-$12 an hour minimum wages to put food on the table during the Christmas season. On the other hand, only 25% of the gains were accounted for my Millennials who now make up 50% of the population.

The other sobering fact is that 100% of America’s economic growth is currently debt-driven. If the government were running a balanced budget as it should at this point in the economic cycle, the country’s GDP growth rate would be zero, and stocks would be in free fall.

As a result, risk in the market is at century highs. The second the government starts to reduce its gargantuan deficit, the stock market will crash.

Trump said the China (FXI) Trade Deal may have to wait until the 2020 election. I told you so. The Volatility Index (VIX) jumped 40% providing a great entry point for one more bite of the apple (AAPL).

Bonds (TLT) soared, opening up one of the best short-selling opportunities of 2019, which I took. The Chinese aren’t going to lift a finger to help Trump get reelected. Farmers are going to have to endure a third year of depression.

The November Nonfarm Payroll blew it away with a 266,000 report, a ten-month high. I’m hiring, that’s for sure. Maybe trade doesn’t matter after all.

China banned US warship visits in response to the US human rights stand on Hong Kong. It’s not exactly a step towards a trade deal, which is why the Dow is diving. The very long overdue correction in the US stock market is starting. Is the marketing finally starting to notice the still weak economic data?

Cyber Monday sales soared by 19% to an all-time record of $9.4 billion. Some 49% of sales were on smartphones, which to me who can bare read one is amazing. The internet was barely functioning on Monday, slowed to a snail’s pace by a glut of business. Now, if I can only get the Victoria’s Secret website to open….

A bigger oil glut looms as OPEC+ went into the Vienna meeting last week. If they don’t cut production substantially, oil prices will crash….again. High prices now are artificially high in front of the Saudi ARAMCO IPO. Avoid all energy plays on pain of death. The end of carbon-based energy forms has begun.

This was a week for the Mad Hedge Trader Alert Service to catapult to new all-time highs.

My long positions have shrunk to my core (MSFT) and (GOOGL).

My Global Trading Dispatch performance held steady at +352.76% for the past ten years, pennies short of an all-time high. My 2019 year-to-date catapulted back up to +52.62%. We closed out November with a respectable +3.07% profit. My ten-year average annualized profit ground back up to +35.28%. 

The coming week will be a noneventful one on the data front.

On Monday, December 9 at 9:00 AM, Consumer Inflation Expectations for November are out.

On Tuesday, December 10 at 2:30 PM, the NFIB Business Optimism Index is released.

On Wednesday, December 11, at 6:15 AM, US Core Inflation is announced.

On Thursday, December 12 at 8:30 AM, Weekly Jobless Claims come out.

On Friday, December 13 at 9:30 AM, November US Retails Sales are printed.

The Baker Hughes Rig Count follows at 2:00 PM.

As for me, I’ll be wrapping presents and doing some last-minute Christmas shopping. Only 200 Christmas trees left to sell.

Good luck and good trading.

John Thomas
CEO & Publisher
The Diary of a Mad Hedge Fund Trader

 

 

 

 

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/12/john-thomas.png 885 633 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-09 07:02:362019-12-09 07:37:27The Market Outlook for the Week Ahead, or the Melt-Up Continues
Mad Hedge Fund Trader

December 9, 2019 - Quote of the Day

Tech Letter

“You may think using Google's great, but I still think it's terrible.” – Said Co-Founder of Google Larry Page

https://www.madhedgefundtrader.com/wp-content/uploads/2019/12/larry-page.png 400 456 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-09 07:00:142019-12-09 06:47:41December 9, 2019 - Quote of the Day
Mad Hedge Fund Trader

December 6, 2019 - MDT Pro Tips A.M.

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-06 09:23:062019-12-06 09:23:06December 6, 2019 - MDT Pro Tips A.M.
Mad Hedge Fund Trader

December 6, 2019

Diary, Newsletter, Summary

Global Market Comments
December 6, 2019
Fiat Lux

Featured Trade:

 

(DECEMBER 4 BIWEEKLY STRATEGY WEBINAR Q&A),
(SPY), (TSLA), (TLT), (BABA), (CCI), (VIX)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-06 09:04:352019-12-06 09:11:43December 6, 2019
Page 1027 of 2205«‹10251026102710281029›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2026. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
Scroll to top